RESUMEN
Aims: The study aims to determine the efficacy and safety of moxifloxacin 0.5% eye drops versus tobramycin 0.3% eye dropsin pediatric population with purulent bacterial conjunctivitis.Study design: Prospective, randomized, investigator-masked, clinical study was conducted on patients.Place and Duration of Study: This study was conducted by the Department of Ophthalmology Veer Chandra Singh GarhwaliGovernment Medical College, Srinagar, Uttarakhand, between March 2018 and February 2019.Methodology: This study included 100 children with purulent discharge and bulbar conjunctival injection. Children either receivedmoxifloxacin 0.5% 4 times a day for 5 days or received tobramycin 0.3% eye drops (every 2 h for 2 days and then 4 times for5 days). Clinical signs were evaluated on days (D) 0, 3, and 7 and cultures on D0 and D7. The primary variable was the clinicalcure (absence of bulbar injection and discharge) on D3 in the worst eye for patients with positive culture on D0.Results: 100 culture-positive cases were included on D0. Moxifloxacin was superior to tobramycin in clinical cure rate on D3 (47.1%vs. 28.7%) P = 0.013) and was non-inferior to tobramycin on D7 (89.8% vs. 78.2%, respectively). Moxifloxacin treatment eradicatedcausative pathogens, including resistant species with a similar resolution rate to tobramycin (89.8% vs. 87.2%).Conclusion: Moxifloxacin 0.5% eye drops provided a more rapid and effective clinical cure than tobramycin 0.3% eye dropsin the treatment of purulent bacterial conjunctivitis in children, with 4 times dosing.
RESUMEN
Aims: The study aims to compare the efficacy of the anti-inflammatory effect of 0.1% dexamethasone sodium and 0.05%difluprednate eye drops after small incision cataract surgery (SICS).Study Design: A prospective, randomized, and clinical study was conducted on patients.Place and Duration of Study: This study was conducted in the Department of Ophthalmology, VCGS Government MedicalCollege, Srinagar, Uttarakhand, between December 2017 and November 2018.Materials and Methods: This study included two groups of 40 patients each (a total of 80 patients). 40 patients in GroupA wererandomly started on 0.1% dexamethasone eye drops postoperatively and another 40 patients in Group B were randomly started0.05% difluprednate eye drops postoperatively. Response to the therapy was recorded on day 1, 7, and 40 on the parametersof post-operative anterior chamber reaction and post-operative visual acuity, and the results were compared.Results: All results were correlated with final visual outcome, and post-operative flare, which showed 0.05% difluprednate, isclinically and statistically more effective in early post-operative period than 0.1% dexamethasone sodium to control inflammationin uneventful SICS.Conclusions: After the comparison of the data in both the groups, the patients started on 0.05% difluprednate eye dropspostoperatively showed better response to therapy (P < 0.0001) with respect to the parameters of best-corrected visual acuityand post-operative flare as compared to the patients started on 0.1% dexamethasone sodium eye drop therapy postoperatively,indicating that 0.05% difluprednate eye drops have a better anti-inflammatory effect.